Related Experiment Video
Updated: Jun 8, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Renovascular hypertension and ischemic nephropathy
Stephen C Textor1, Lilach Lerman
1Mayo Clinic, Rochester, Minnesota, USA. textor.stephen@mayo.edu
American Journal of Hypertension
|September 25, 2010
Summary
Atherosclerotic renal-artery stenosis (ARAS) is a common cause of secondary hypertension. While medical management is effective for many, revascularization benefits remain unproven in recent trials, necessitating individualized patient care.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Hypertension Research
Background:
- Renovascular disease, particularly atherosclerotic renal-artery stenosis (ARAS), is a significant contributor to secondary hypertension and renal dysfunction.
- ARAS is strongly associated with increased cardiovascular risk and develops through complex pressor signals like renin-angiotensin system (RAS) activation.
- Reduced renal perfusion in ARAS leads to microvascular dysfunction, vascular rarefaction, and interstitial fibrosis, impairing kidney function.
Purpose of the Study:
- To review the current understanding of renovascular disease, its impact on hypertension and renal function, and the evolving treatment landscape.
- To evaluate the evidence for and against renal revascularization in patients with atherosclerotic renal-artery stenosis.
- To discuss future directions in managing patients with ARAS, emphasizing individualized therapy and potential regenerative approaches.
Main Methods:
- Review of epidemiologic studies and clinical trials concerning atherosclerotic renal-artery stenosis (ARAS).
- Analysis of the pathophysiological mechanisms underlying hypertension and renal dysfunction in ARAS.
- Discussion of current medical management strategies and the outcomes of renal revascularization trials.
Main Results:
- Effective blood pressure control is achievable for many patients with ARAS through advances in antihypertensive therapy and risk factor management.
- Recent prospective randomized trials have not demonstrated compelling benefits of renal revascularization (stents or surgery) over medical therapy alone.
- Limited recovery of kidney function is expected once interstitial fibrosis is established, highlighting the importance of early intervention.
Conclusions:
- Individualized treatment strategies are crucial for patients with ARAS to optimize both blood pressure control and renal function.
- Further research into staging tools and regenerative medicine holds promise for improving future outcomes in ARAS.
- Despite observational data, current evidence does not strongly support routine revascularization for ARAS when optimal medical therapy is provided.
Related Concept Videos
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:29Acute Kidney Injury II: Pathophysiology
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...